GSK has reached a licensing agreement with mRNA vaccine developer CureVac worth up to €1.4bn to develop its vaccines for flu, Covid-19 and avian flu.
葛兰素史克(GSK)与mRNA疫苗开发商CureVac达成了一项价值高达14亿欧元的许可协议，以开发其针对流感、新冠和禽流感的疫苗。
您已阅读6%（215字），剩余94%（3317字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。